This proposed text is designed to provide a useful and comprehensive resource and state-of-the-art overview to readers about vascular damage potentially induced by antineoplastic drugs.
Thanks to more and more effective antineoplastic treatments the survival of cancer patients is enormously increasing, but at the same time it is increasing the burden of related cardiovascular complications that affect morbidity and mortality. On this basis a new branch of cardiology has been developed, that is Cardio-Oncology. The aim is to prevent cardiovascular complications related to cancer therapy and to facilitate and avoid interruption of antineoplastic drugs due to the occurrence of cardiovascular damage. An increasing attention has been given to cardiac damage, while, until today, vascular complications have been poorly evaluated.
The aim of this book is to focus on vascular complications related to cancer treatment, to guide the clinician at facing, during his every day practice, cardiovascular toxicity in cancer and hematologic patients.
The proposed sections of the book have been structured to review the molecular mechanisms underlying vascular damage induced by new and old treatments, to describe the various manifestations of vascular disease that may range from artery to venous disease (including coronary artery disease, peripheral arterial disease, venous thromboembolism and pulmonary hypertension), and to provide advice to monitor patients undergoing onco-hematologic treatments in order to prevent and eventually manage vascular damage.
This book will address resident and fellow physicians, medical oncologists, cardiologists, general practitioners and all those who take care of these patients.
All invited authors will be recognized experts in their field, and leading international researchers on these topics. The editor has worked with these expert colleagues on a variety of other projects. The authors will provide their manuscript according to current literature and clinical research studies.
The book does not seek to duplicate or replace other current resources. Rather, it will create a comprehensive yet concise resource on this emerging topic that is not adequately covered by any current literature.
Introduction.- Mechanisms of Cardiovascular Damage Induced by Traditional Chemotherapy.- Molecular Mechanisms of Cardiovascular Damage Induced by Anti HER2 Therapies.- Cardiovascular Damage Induced by Radiotherapy.- Cardiovascular Damage Induced by Anti-VEGF Therapy.- Cardiovascular Damage Induced by Anti-BCR-ABL TKIs.- Heart Failure and Left Ventricular Dysfunction.- Coronary Artery Disease.- Peripheral Artery Disease and Stroke.- Valvular Heart Disease.- Arterial Hypertension.- Atrial Fibrillation in Cancer.- Management of QT Prolongation Induced by Anti-cancer Drugs.- Pulmonary Hypertension Induced by Anti-cancer Drugs.- Venous Thromboembolism.- Early Detection of Cardiac Damage.- Diagnosis of Cardiac Damage: Role of Stress Echo.- Early Detection and Monitoring of Vascular Damage.- Prevention and Clinical Management of Cardiovascular Damage Induced by Anticancer Drugs: Need for Early Biomarkers and Cardio- and Vasculo-Protection in Personalized Therapy.- Cardiovascular Damage in Clinical Trials.
Antonio Russo, MD, PhD
Full Professor of Medical Oncology
Department of Surgical, Oncological and Oral Sciences (Di.Chir.On.S.)
University of Palermo, Italy
Director of Medical Oncology Section, University Hospital P. Giaccone
Giuseppina Novo, MD, PhD
Associate Professor of Cardiology
Biomedic Department of Internal Medicine and Specialities (DIBIMIS) University of Palermo, Italy
Division of Cardiology, University Hospital P. Giaccone
Patrizio Lancellotti, MD, PhD
University of Liège Hospital, GIGA Cardiovascular Sciences
Department of Cardiology
CHU Sart Tilman, Liège, Belgium
Gruppo Villa Maria Care and Research, Anthea Hospital
Antonio Giordano, MD PhD
Director, Sbarro Institute for Cancer Research and Molecular Medicine and Center of Biotechnology
College of Science and Technology
Fausto J. Pinto, MD, PhD, FESC, FACC, FSCAI, FASE
Professor, University Hospital Santa Maria, CHLN
University of Lisbon, Portugal
Dept. of Cardiology
Av Prof Egas Moniz
Lisboa 1649-028 Portugal
This book is designed to provide a useful and comprehensive resource and state-of-the-art overview to readers about cardiovascular damage potentially induced by antineoplastic drugs. Thanks to more and more effective antineoplastic treatments, the survival of cancer patients is increasing at an exponential rate. However, the burden of related cardiovascular complications that affect morbidity and mortality are also on the rise. A new branch of cardiology, Cardio-Oncology, was developed to combat this trend. The aim of its conception is to prevent cardiovascular complications related to cancer therapy and to facilitate and avoid interruption of antineoplastic drugs due to the occurrence of cardiovascular damage. The text focuses on cardiovascular complications related to cancer treatment and reviews the pathophysiological mechanisms leading to cardiovascular toxicity related to various antineoplastic drugs. Diagnostic modalities for early diagnosis are also discussed, followed by preventive and therapeutic strategies.
Cardiovascular Complications in Cancer Therapy serves as a valuable resource for residents, fellow physicians, medical oncologists, cardiologists, and general practitioners and all those who take care of these patients.
Provides a comprehensive yet concise resource.
Provides a guide for the clinician facing cardiovascular toxicity in cancer and hematologic patients.
Written by experts in the field.
Provides a comprehensive yet concise resource
Provides a guide for the clinician facing cardiovascular toxicity in cancer and hematologic patients
Written by experts in the field